An interventional study of Paclitaxel in Malignant Airway Obstruction Secondary to Non-small Cell Lung Cancer, sponsored by Mercator MedSystems, Inc.. Completed at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-20.
Sponsored by Mercator MedSystems, Inc. · Not applicable, Interventional, and Supportive care
Assess the safety and feasibility of local oncological drug delivery into the bronchial wall after recanalization of subjects with malignant airway obstruction. Safety and feasibility (technical success) will be assessed.
This localized delivery is intended as an adjunct therapy and all subjects will receive standard of care oncology therapy as determined by their treating physicians.
154 studies on the registry are indexed under Airway Obstruction; 30 are open to participants now.
This study's enrollment of 20 is below the median of 56 across 92 interventional studies indexed under Airway Obstruction.
Browse Airway Obstruction studies →Mercator MedSystems, Inc. is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Presence or recent history of any systemic disorder or conditions, such as:
Drug: Paclitaxel
Treatment safety
Adverse Events (AEs), Serious Adverse Events (SAEs), and all Unanticipated Adverse Device Effects (UADEs)
Time frame: 12 weeks
Technical success
Device deployment and infusion success
Time frame: procedure day
Airway patency improvements
Time frame: 6 weeks
Quality of Life
Time frame: 12 weeks
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mercator MedSystems, Inc.